Logo Logo
Hilfe
Hilfe
Switch Language to English

Wang, Jie ORCID logoORCID: https://orcid.org/0000-0003-4338-2873; Huang, Qi; Chen, Xing; You, Zhiwen; He, Kun; Mao, Xiaoxie; Huang, Yiyun; Franzmeier, Nicolai ORCID logoORCID: https://orcid.org/0000-0001-9736-2283; Schöll, Michael; Guo, Tengfei; Zhao, Jun; Guan, Yihui; Ni, Ruiqing; Li, Binyin und Xie, Fang ORCID logoORCID: https://orcid.org/0000-0003-2667-281X (2025): Prediction of longitudinal synaptic loss in Alzheimer's disease using tau PET and plasma biomarkers. In: Alzheimer's & Dementia, Bd. 21, Nr. 5, e70333 [PDF, 2MB]

Abstract

INTRODUCTION

We investigated the associations of longitudinal synaptic loss and cognitive decline with tau burden and plasma biomarkers in Alzheimer's disease (AD).

METHODS

Twenty cognitively impaired (CI) individuals and 16 healthy controls (HC) underwent cognitive and plasma biomarker assessments, amyloid positron emission tomography (PET), tau PET, and synaptic density PET; after 1 year, tau and synaptic density PET were repeated. The relationships among tau burden, plasma biomarkers, synaptic density, and cognition were investigated.

RESULTS

The CI group had more longitudinal synapse loss and tau deposition than HCs. Longitudinal synaptic loss was positively associated with longitudinal cognitive decline, negatively with longitudinal tau deposition. Plasma glial fibrillary acidic protein (GFAP) mediates the relationship between longitudinal tau deposition and longitudinal synaptic loss. Tau burden, plasma phosphorylated tau181, and GFAP could predict longitudinal synaptic loss and cognitive decline.

CONCLUSIONS

The CI group had more longitudinal synapse loss and tau burden increases than HCs. Tau pathology and plasma GFAP could predict longitudinal synapse loss and cognitive decline.

Dokument bearbeiten Dokument bearbeiten